FDA Law SSRN Reading List – October and November (Part 2 of 2)

Here are three more new and noteworthy articles from October and November, including Professor Robin Feldman’s new empirical study of the pharmaceutical industry.

Continue reading “FDA Law SSRN Reading List – October and November (Part 2 of 2)”